[go: up one dir, main page]

FR20C1018I1 - Pharmaceutical composition comprising glycopyrrolate and a beta2 adrenergic receptor agonist - Google Patents

Pharmaceutical composition comprising glycopyrrolate and a beta2 adrenergic receptor agonist

Info

Publication number
FR20C1018I1
FR20C1018I1 FR20C1018C FR20C1018C FR20C1018I1 FR 20C1018 I1 FR20C1018 I1 FR 20C1018I1 FR 20C1018 C FR20C1018 C FR 20C1018C FR 20C1018 C FR20C1018 C FR 20C1018C FR 20C1018 I1 FR20C1018 I1 FR 20C1018I1
Authority
FR
France
Prior art keywords
sup
glycopyrrolate
pharmaceutical composition
receptor agonist
adrenergic receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1018C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32607514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1018(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR20C1018I1 publication Critical patent/FR20C1018I1/en
Application granted granted Critical
Publication of FR20C1018I2 publication Critical patent/FR20C1018I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Compositions Of Oxide Ceramics (AREA)

Abstract

A pharmaceutical composition containing (A) glycopyrrolate; and (B) a compound of formula Iin free or salt or solvate form, wherein W, R<sup>x</sup>, R<sup>y</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>and R<sup>7</sup>have the meanings as indicated in the specification, together with at least one pharmaceutically acceptable carrier. The composition is useful in the treatment of inflammatory or obstructive airways diseases.
FR20C1018C 2004-05-18 2020-05-27 Pharmaceutical composition comprising glycopyrrolate and a beta2 adrenergic receptor agonist Active FR20C1018I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0411056.5A GB0411056D0 (en) 2004-05-18 2004-05-18 Organic compounds
EP05749635A EP1755590B1 (en) 2004-05-18 2005-05-17 Combination of glycopyrrolate and a beta2 adrenoceptor agonist
PCT/EP2005/005354 WO2005110402A1 (en) 2004-05-18 2005-05-17 Combinations of glycopyrrolate and beta2 adrenoceptor agonists

Publications (2)

Publication Number Publication Date
FR20C1018I1 true FR20C1018I1 (en) 2020-07-10
FR20C1018I2 FR20C1018I2 (en) 2023-11-03

Family

ID=32607514

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1018C Active FR20C1018I2 (en) 2004-05-18 2020-05-27 Pharmaceutical composition comprising glycopyrrolate and a beta2 adrenergic receptor agonist

Country Status (33)

Country Link
US (6) US20080267886A1 (en)
EP (3) EP3603634B1 (en)
JP (2) JP5567252B2 (en)
KR (2) KR20130018429A (en)
CN (1) CN1953745A (en)
AT (1) ATE521348T1 (en)
AU (1) AU2005244439C1 (en)
BE (1) BE2020C517I2 (en)
BR (1) BRPI0511327B8 (en)
CA (1) CA2563302C (en)
CY (4) CY1112086T1 (en)
DK (2) DK1755590T3 (en)
EC (1) ECSP066950A (en)
ES (2) ES2775979T3 (en)
FR (1) FR20C1018I2 (en)
GB (1) GB0411056D0 (en)
HU (3) HUE048936T2 (en)
IL (1) IL179013A (en)
LT (3) LT2228064T (en)
LU (1) LUC00155I2 (en)
MA (1) MA28598B1 (en)
MX (1) MXPA06013382A (en)
NO (2) NO334760B1 (en)
NZ (1) NZ550369A (en)
PL (2) PL1755590T3 (en)
PT (2) PT1755590E (en)
RU (1) RU2388465C2 (en)
SE (1) SE1755590T5 (en)
SG (1) SG153836A1 (en)
SI (2) SI1755590T1 (en)
TN (1) TNSN06377A1 (en)
WO (1) WO2005110402A1 (en)
ZA (1) ZA200608123B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
JP4991693B2 (en) * 2005-03-16 2012-08-01 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Combinations of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
CA2607391A1 (en) * 2005-04-23 2006-11-02 Boehringer Ingelheim International Gmbh Combination of medicaments to be inhaled, containing a betamimetic agent and a steroid in addition to an anticholinergic agent
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0523655D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
EP1878722A1 (en) * 2006-07-13 2008-01-16 Novartis AG Quinolinone derivatives and their pharmaceutical compositions
BRPI0713951B8 (en) 2006-06-30 2021-05-25 Novartis Ag quinazoline derivatives, and pharmaceutical composition
EP1938822A1 (en) * 2006-12-21 2008-07-02 Novartis AG Combination therapy for the treatment of airways disease
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL2435025T3 (en) * 2009-05-29 2017-08-31 Pearl Therapeutics, Inc. Respiratory delivery of active agents
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
ES2468840T7 (en) 2009-12-23 2023-11-29 Chiesi Farm Spa Combination therapy for COPD
KR101738712B1 (en) 2009-12-23 2017-05-22 키에시 파르마슈티시 엣스. 피. 에이. Combination therapy for copd
CN103501776A (en) 2011-02-17 2014-01-08 西普拉有限公司 Composition of glycopyrrolate and a beta2-agonist
KR101317924B1 (en) * 2011-05-17 2013-10-16 김동진 Synthetics method of Glycopyrrolate and pharmaceutical formulations containing this active ingredient
US20150202297A1 (en) 2012-07-05 2015-07-23 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose and a ternary component
US20150202148A1 (en) 2012-07-05 2015-07-23 Arven llac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose
KR101460694B1 (en) * 2012-09-07 2014-11-11 성광제약주식회사 New synthetic method of glycopyrrolate and pharmaceutical formulations containing this active ingredient
CN103784401A (en) * 2012-10-29 2014-05-14 北京市丰硕维康技术开发有限责任公司 Solution-type metered dose inhalation aerosol for treating respiratory diseases and preparation method thereof
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
KR102232806B1 (en) 2013-02-28 2021-03-29 더미라, 인코포레이티드 Glycopyrrolate salts
EP2968152B2 (en) 2013-03-15 2022-06-22 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
JP6563950B2 (en) 2013-12-30 2019-08-21 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Stable pressurized aerosol solution composition of a combination of glycopyrronium bromide and formoterol
CN106604720B (en) 2014-09-09 2020-03-10 维克多瑞有限公司 Formulations, methods and apparatus comprising glycopyrronium
KR20180128450A (en) * 2016-04-11 2018-12-03 수벤 라이프 사이언시스 리미티드 Topical spray formulation of glycopyrrolate
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
WO2020217143A1 (en) * 2019-04-23 2020-10-29 Glenmark Pharmaceutical Limited Inhalable dry powder composition comprising gly copyrronium, indacaterol and fluticasone
CN112804997B (en) * 2019-06-03 2022-02-22 广州谷森制药有限公司 Inhalable formulations containing indacaterol maleate and glycopyrronium bromide solutions
US20220395454A1 (en) 2019-12-02 2022-12-15 Chiesi Farmaceutici S.P.A. Stainless steel can for pressurised metered dose inhalers

Family Cites Families (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
IT1016489B (en) 1974-03-18 1977-05-30 Isf Spa INHALER
JPS6235216A (en) 1985-08-09 1987-02-16 Noritoshi Nakabachi Method and device for measuring thickness of heterogeneous material layer nondestructively
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
US5416013A (en) 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
PT100441A (en) 1991-05-02 1993-09-30 Smithkline Beecham Corp PIRROLIDINONES, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE
US5451700A (en) 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
EP0519748B1 (en) 1991-06-21 1998-09-02 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
DK0600880T3 (en) 1991-08-30 2004-04-13 Vertex Pharma Interleukin 1 beta protease and interleukin 1 beta protease inhibitors
EP0547699A1 (en) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
WO1993014777A1 (en) 1992-01-31 1993-08-05 Merck & Co., Inc. PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
JP3386125B2 (en) 1992-02-21 2003-03-17 メルク エンド カンパニー インコーポレーテッド Peptidyl derivatives as interleukin-1β converting enzyme inhibitors
WO1993018007A1 (en) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Novel carbostyril derivative
JP3192424B2 (en) 1992-04-02 2001-07-30 スミスクライン・ビーチャム・コーポレイション Compounds for the treatment of allergic or inflammatory diseases
JP3251587B2 (en) 1992-04-02 2002-01-28 スミスクライン・ビーチャム・コーポレイション Compounds useful for treating inflammatory diseases and inhibiting tumor necrosis factor production
HU225869B1 (en) 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
JPH08500242A (en) 1992-06-24 1996-01-16 メルク エンド カンパニー インコーポレーテッド DNA encoding interleukin-1β precursor convertase
US5739279A (en) 1992-07-31 1998-04-14 Pfizer Inc. Peptidyl 4-amino-2,2-difluoro-3-oxo-1,6-hexanedioic acid derivatives as antiinflammatory agents
US5395958A (en) 1992-09-30 1995-03-07 Mitsubishi Kasei Corporation Cyclopropene derivatives
CA2109646C (en) 1992-11-24 2000-03-07 Gaston O. Daumy Para-nitroanilide peptides
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5656600A (en) 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5411985A (en) 1993-05-17 1995-05-02 Merck & Co., Inc. Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme
JPH0789951A (en) 1993-06-03 1995-04-04 Sterling Winthrop Inc Interleukin-1β convertase inhibitor
ES2122145T3 (en) 1993-06-04 1998-12-16 Vertex Pharma PEPTIDIC PHOSPHINYLOXIMETHYL-KETONES AS INHIBITORS OF THE CONVERTED ENZYME OF INTERLEUKIN-1 BETA.
DK0628550T3 (en) 1993-06-08 1998-09-28 Vertex Pharma Pyridazine as interleukin-1 beta-converted enzyme inhibitors
DE4326959C2 (en) 1993-08-12 1995-07-06 Henkel Kgaa Use of fatty acid N-alkylpolyhydroxyalkylamides
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
PT995457E (en) 1995-12-07 2004-07-30 Jago Res Ag NOZZLE FOR AN INHALER FOR DISTRIBUTION REPLACED DOSEADAMENT OF A PHARMACOLOGICALLY DRY PO
US5843904A (en) 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US6610683B2 (en) 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
ATE215953T1 (en) 1996-09-12 2002-04-15 Idun Pharmaceuticals Inc NEW TRICYCLIC COMPOUNDS WITH ICE/CED-3 PROTEASE FAMILY INHIBITING PROPERTIES
EP0929311B8 (en) 1996-09-12 2006-02-01 Idun Pharmaceuticals, Inc. INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS
CA2265928A1 (en) 1996-09-12 1998-03-19 Idun Pharmaceuticals, Incorporated C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
WO1998021183A1 (en) 1996-11-11 1998-05-22 Noe Christian R Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing the same and their use in medicaments
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
US6054487A (en) 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
CA2282845A1 (en) 1997-03-18 1998-09-24 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
AR016384A1 (en) 1997-07-30 2001-07-04 Smithkline Beecham Corp INHIBITORS OF CASPASAS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITORS OF CASPASAS AND USE OF CASPASE INHIBITORS TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF APOPTOSIS AND DISORDERS ASSOCIATED WITH EXCESSIVE ACTIVITY ILL-1 CONVERT.
WO1999016766A1 (en) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Benzodioxole derivatives
GB9723589D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723566D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (en) 1998-01-31 2003-01-31 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
AR017457A1 (en) 1998-02-14 2001-09-05 Glaxo Group Ltd COMPOUNDS DERIVED FROM 2- (PURIN-9-IL) -TETRAHIDROFURAN-3,4-DIOL, PROCESSES FOR THEIR PREPARATION, COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THERAPY FOR THE TREATMENT OF INFLAMMATORY DISEASES.
HU227920B1 (en) 1998-03-19 2012-06-28 Vertex Pharma Inhibitors of caspases, pharmaceutical compositions comprising thereof and their use
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
AR019322A1 (en) 1998-06-18 2002-02-13 Smithkline Beecham Corp SULFONYL DERIVATIVES REPLACED BY HETEROCICLO-ETANODIONANILINA REPLACED BY HETEROCICLO, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND ITS USE FOR LAMANUFACTURE OF A MEDICINAL PRODUCT
AP2000002016A0 (en) 1998-06-23 2000-12-31 Glaxo Group Ltd 2-(Purin-9-yl) Tetrahydrofuran-3,4-diol derivatives.
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813565D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
CN1146616C (en) 1998-06-30 2004-04-21 陶氏环球技术公司 Polymer polyols and a process for the prodn. thereof
CN1158996C (en) 1998-07-24 2004-07-28 杰格研究股份公司 Medicinal aerosol for mulations
ATE331726T1 (en) 1998-10-16 2006-07-15 Pfizer ADENINE DERIVATIVES
EP2266548B1 (en) 1998-11-13 2020-05-20 Jagotec AG Dry powder for inhalation
GB9902689D0 (en) 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (en) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
YU25500A (en) 1999-05-11 2003-08-29 Pfizer Products Inc. Process for the synthesis of nucleosite analogues
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
HRP20020158B1 (en) 1999-08-21 2007-08-31 Altana Pharma Ag Action of synergistic combination
AU7127600A (en) 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
CO5180581A1 (en) 1999-09-30 2002-07-30 Pfizer Prod Inc COMPOUNDS FOR THE TREATMENT OF THE ISCHEMIA PHARMACEUTICAL TIONS THAT CONTAIN THEM FOR THE TREATMENT OF THE ISCHEMIA
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US6369115B1 (en) 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
JP2003533448A (en) 2000-04-27 2003-11-11 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Novel long-acting beta mimic, process for its preparation and its use as a medicament
TWI227240B (en) 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
GB0015727D0 (en) 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
AU6610001A (en) 2000-06-27 2002-01-08 S A L V A T Lab Sa Carbamates derived from arylalkylamines
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10038639A1 (en) 2000-07-28 2002-02-21 Schering Ag New and known N-aryl 2-hydroxy-omega-arylalkanamide derivatives, useful e.g. for treating inflammatory diseases such as rheumatism
ES2317922T3 (en) 2000-08-05 2009-05-01 Glaxo Group Limited DERIVATIVES OF BETA-CARBOTIOATO 17, ALFA-ACRILCARBONILOXILOXI ANDROSTANO AS ANTI-INFLAMMATORY AGENTS.
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
US20020193392A1 (en) 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
PE20020719A1 (en) 2000-12-22 2002-10-11 Almirall Prodesfarma Ag QUINUCLIDINE CARBAMATE DERIVATIVES AS ANTIMUSCARINIC AGENTS M3
AU2002238471B2 (en) 2000-12-28 2007-06-28 Almirall, S.A. Quinuclidine derivatives and their use as M3 antagonists
US20020179087A1 (en) 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
EP1366025B1 (en) 2001-03-08 2007-06-27 Glaxo Group Limited Agonists of beta-adrenoreceptors
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
CA2443600A1 (en) 2001-04-19 2002-10-31 Vertex Pharmaceuticals Incorporated Heterocyclyldicarbamides as caspase inhibitors
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
EE200300586A (en) 2001-05-25 2004-04-15 Pfizer Inc. Combination of adenosine A2A receptor agonist and anticholinergic agent for the treatment of obstructive airways diseases
ATE399174T1 (en) 2001-06-12 2008-07-15 Glaxo Group Ltd NEW ANTI-INFLAMMATORY 17.ALPHA.-HETEROCYCLIC ESTERS OF 17.BETA.-CARBOTHIOATE ANDROSTANE DERIVATIVES
DK2327766T3 (en) 2001-06-21 2016-03-07 Basf Enzymes Llc nitrilases
ITMI20010357U1 (en) 2001-06-28 2002-12-30 Plastiape Spa INHALER DEVICE
BRPI0212455B8 (en) 2001-09-14 2021-05-25 Glaxo Group Ltd compound derived from phenethanolamine for the treatment of respiratory diseases, pharmaceutical formulation, combination, and use thereof
BR0212983A (en) 2001-10-17 2004-10-13 Ucb Sa Compound, Compound Use, and, Synthesis Intermediates
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
MY130622A (en) 2001-11-05 2007-07-31 Novartis Ag Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
HU229504B1 (en) 2001-11-09 2014-01-28 Gilead Sciences A2b adenosine receptor antagonists
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003048181A1 (en) 2001-12-01 2003-06-12 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
PL211250B1 (en) 2001-12-20 2012-04-30 Chiesi Farma Spa 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists
WO2003072592A1 (en) 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003062259A2 (en) 2002-01-21 2003-07-31 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
US6933410B2 (en) 2002-03-08 2005-08-23 Novartis Ag Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine
PL373043A1 (en) 2002-03-26 2005-08-08 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP1490317A1 (en) 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE60318192T2 (en) 2002-04-10 2008-04-30 The University Of Virginia Patent Foundation USE OF A2A ADENOSINE RECEPTOR AGONISTS AND ANTI-PATHOGENIC AGENTS CONTAINING COMBINATIONS IN THE TREATMENT OF INFLAMMATORY DISEASES
CA2481320A1 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
ES2206021B1 (en) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRROLIDINIO.
EP1497261B1 (en) 2002-04-25 2007-12-19 Glaxo Group Limited Phenethanolamine derivatives
WO2003099764A1 (en) 2002-05-28 2003-12-04 Theravance, Inc. ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS
ES2201907B1 (en) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF INDOLILPIPERIDINE AS POWERFUL ANTIHISTAMINIC AND ANTIALERGIC AGENTS.
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10224888A1 (en) 2002-06-05 2003-12-24 Merck Patent Gmbh pyridazine
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (en) 2002-06-10 2003-12-18 Merck Patent Gmbh New 1-acyl-3-phenyl-5,6-dihydro-4H-pyridazine derivatives, are phosphodiesterase IV inhibitors useful e.g. for treating asthma, allergy, inflammation, autoimmune diseases or myocardial diseases
DE10227269A1 (en) 2002-06-19 2004-01-08 Merck Patent Gmbh thiazole
ATE356808T1 (en) 2002-06-25 2007-04-15 Merck Frosst Canada Ltd 8-(BIARYL)QUINOLINE PDE4 INHIBITORS
EP1519922A1 (en) 2002-07-02 2005-04-06 Merck Frosst Canada &amp; Co. Di-aryl-substituted ethane pyridone pde4 inhibitors
ES2204295B1 (en) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF QUINUCLIDINE-AMIDE.
WO2004005229A1 (en) 2002-07-08 2004-01-15 Pfizer Products Inc. Modulators of the glucocorticoid receptor
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AR040661A1 (en) 2002-07-26 2005-04-13 Theravance Inc CRYSTAL DICHLORHYDRATE OF N- {2 - [- ((R) -2-HYDROXI-2-PHENYLETHYLAMINE) PHENYL] ETIL} - (R) -2 HYDROXY-2- (3-FORMAMIDE-4-HYDROXYPHENYL) ETHYLAMINE, RECEIVER AGONIST BETA 2 ADRENERGIC
PE20050130A1 (en) * 2002-08-09 2005-03-29 Novartis Ag ORGANIC COMPOUNDS
AU2003260371A1 (en) 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-n-oxide-derivatives
HRP20050198A2 (en) 2002-08-10 2006-04-30 Altana Pharma Ag PIPERIDINE-PYRIDAZONE AND PTHALAZONE AS INHIBITORS OF PDE4
WO2004018449A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
EP1556369A1 (en) 2002-08-10 2005-07-27 ALTANA Pharma AG Pyridazinone-derivatives as pde4 inhibitors
WO2004018431A2 (en) 2002-08-17 2004-03-04 Altana Pharma Ag Novel phenanthridines
CA2495603A1 (en) 2002-08-17 2004-03-04 Altana Pharma Ag Benzonaphthyridines with pde 3/4 inhibiting activity
GB0219512D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
WO2004018429A2 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7288562B2 (en) 2002-08-23 2007-10-30 Ranbaxy Laboratories Limited Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
HRP20050185A2 (en) 2002-08-29 2006-05-31 Boehringer Ingelheim Pharmaceuticals Inc. -3 (sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
EP1539164B1 (en) 2002-08-29 2006-12-20 ALTANA Pharma AG 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
AU2003273805B8 (en) 2002-08-29 2010-06-17 Takeda Gmbh 3-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
JP2006096662A (en) 2002-09-18 2006-04-13 Sumitomo Pharmaceut Co Ltd Novel 6-substituted uracil derivatives and therapeutic agents for allergic diseases
JP2004107299A (en) 2002-09-20 2004-04-08 Japan Energy Corp Novel 1-substituted uracil derivatives and therapeutic agents for allergic diseases
AU2003270783C1 (en) 2002-09-20 2010-05-20 Merck Sharp & Dohme Corp. Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
DE10246374A1 (en) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 4-(2-alkylamino-1-hydroxyethyl)-3-alkoxy-benzene-1,2-diol derivatives, are beta-mimetics having a long duration of action, useful e.g. for treating asthma, chronic obstructive pulmonary disease or arrhythmia
PL376396A1 (en) 2002-10-11 2005-12-27 Pfizer Inc. Indole derivatives as beta-2 agonists
US20060205790A1 (en) 2002-10-22 2006-09-14 Coe Diane M Medicinal arylethanolamine compounds
JP2006506379A (en) 2002-10-23 2006-02-23 グレンマーク・ファーマシューティカルズ・リミテッド Novel tricyclic compounds useful for the treatment of inflammatory and allergic diseases: methods for their preparation and pharmaceutical compositions containing them
AU2003286143A1 (en) 2002-10-28 2004-05-13 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253220A1 (en) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 2-(N-phenylalkyl-amino)-1-phenyl-ethanol derivatives, are beta-adrenergic agents especially useful for treating inflammatory and obstructive respiratory diseases such as asthma or COPD
DE10253426B4 (en) 2002-11-15 2005-09-22 Elbion Ag Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and methods for their preparation
DE10253282A1 (en) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treatment of chronic obstructive pulmonary disease, using new or known N-substituted 2-amino-1-(benz-(1,4)-oxazin-3-on-8-yl)-ethanol derivative beta-mimetic agents, suitable for once-daily administration
DE10261874A1 (en) 2002-12-20 2004-07-08 Schering Ag Nonsteroidal anti-inflammatories
KR101026819B1 (en) 2003-01-09 2011-04-04 아스테라스 세이야쿠 가부시키가이샤 Pyrrolopyridazine derivatives
WO2004066920A2 (en) 2003-01-21 2004-08-12 Merck & Co. Inc. 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators
TWI324150B (en) 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
PE20100399A1 (en) 2003-04-02 2010-06-01 Novartis Ag PROCEDURE TO PREPARE OXY- (1H) -QUINOLIN-2-ONAS 5- (ALPHA-HALOACETIL) -8-SUBSTITUTED
US7745462B2 (en) 2003-04-04 2010-06-29 Novartis Ag Quinoline-2-one derivatives for the treatment of airways diseases
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
ES2298757T3 (en) 2003-06-04 2008-05-16 Pfizer Inc. DERIVATIVES OF Z-AMINO-PIRIDINA AS BETA-2 ADRECORRECEPTORS AGONISTS.
CA2527769A1 (en) 2003-06-11 2004-12-16 Merck Frosst Canada Ltd. 7- (1, 3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors
TW200510298A (en) 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
WO2004111044A1 (en) 2003-06-17 2004-12-23 Glenmark Pharmaceuticals Ltd. Tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation
SE527189C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
EP1720577A2 (en) * 2004-02-27 2006-11-15 Altana Pharma AG Ciclesonide and glycopyrronium combination
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US20060239935A1 (en) * 2005-04-23 2006-10-26 Boehringer Ingelheim International Gmbh Compositions for inhalation
EP2778064A1 (en) 2013-03-14 2014-09-17 Airbus Operations GmbH Passenger services provisioning for a means of transport
CA2956257C (en) 2014-09-25 2022-07-12 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals

Also Published As

Publication number Publication date
SI2228064T1 (en) 2020-04-30
SG153836A1 (en) 2009-07-29
NO2014020I2 (en) 2014-08-07
LTC2228064I2 (en) 2022-05-10
JP5567252B2 (en) 2014-08-06
US20190282561A1 (en) 2019-09-19
BRPI0511327B1 (en) 2019-08-06
AU2005244439C1 (en) 2014-09-11
LTPA2020509I1 (en) 2020-07-10
FR20C1018I2 (en) 2023-11-03
SE1755590T5 (en) 2015-01-20
NO2014020I1 (en) 2014-08-07
CY1122863T1 (en) 2020-11-25
BRPI0511327A (en) 2007-12-04
HK1105579A1 (en) 2008-02-22
PT1755590E (en) 2011-10-27
IL179013A0 (en) 2007-05-15
DK1755590T3 (en) 2011-12-12
AU2005244439B2 (en) 2009-07-30
CY2020013I2 (en) 2020-11-25
EP2228064B1 (en) 2019-12-11
PL2228064T3 (en) 2020-06-01
PL1755590T3 (en) 2012-01-31
LUC00155I2 (en) 2021-02-17
PT2228064T (en) 2020-08-25
CY2020013I1 (en) 2020-11-25
DK2228064T3 (en) 2020-03-16
GB0411056D0 (en) 2004-06-23
LTC1755590I2 (en) 2018-05-10
ECSP066950A (en) 2006-12-20
US20210236478A1 (en) 2021-08-05
IL179013A (en) 2012-02-29
EP2228064A2 (en) 2010-09-15
CY2014014I1 (en) 2015-11-04
ES2370647T3 (en) 2011-12-21
WO2005110402A1 (en) 2005-11-24
MA28598B1 (en) 2007-05-02
BRPI0511327B8 (en) 2021-05-25
RU2388465C2 (en) 2010-05-10
ATE521348T1 (en) 2011-09-15
EP1755590A1 (en) 2007-02-28
MXPA06013382A (en) 2007-03-23
US20080267886A1 (en) 2008-10-30
LTPA2014015I1 (en) 2014-04-25
HUS1400013I1 (en) 2016-11-28
BE2020C517I2 (en) 2024-08-08
ZA200608123B (en) 2008-07-30
ES2775979T3 (en) 2020-07-28
EP1755590B1 (en) 2011-08-24
EP2228064A3 (en) 2011-11-02
LT2228064T (en) 2020-03-25
NO334760B1 (en) 2014-05-19
RU2006144810A (en) 2008-06-27
AU2005244439A1 (en) 2005-11-24
JP2012236833A (en) 2012-12-06
CY1112086T1 (en) 2015-11-04
EP3603634B1 (en) 2025-02-12
KR20070011519A (en) 2007-01-24
HUS2000014I1 (en) 2020-07-28
HUE048936T2 (en) 2020-09-28
US20130237564A1 (en) 2013-09-12
KR101360556B9 (en) 2022-08-12
TNSN06377A1 (en) 2008-02-22
KR101360556B1 (en) 2014-02-21
KR20130018429A (en) 2013-02-21
CA2563302A1 (en) 2005-11-24
SI1755590T1 (en) 2011-12-30
NO20065787L (en) 2006-12-14
CA2563302C (en) 2012-08-28
EP3603634A1 (en) 2020-02-05
US20160101097A1 (en) 2016-04-14
NZ550369A (en) 2009-11-27
JP2007538036A (en) 2007-12-27
US20180071276A1 (en) 2018-03-15
CN1953745A (en) 2007-04-25
LUC00155I1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
FR20C1018I1 (en) Pharmaceutical composition comprising glycopyrrolate and a beta2 adrenergic receptor agonist
NO2010023I1 (en) Vernacalant or a solvate or pharmaceutically acceptable salt thereof, including including vernacalan hydrochloride
DE602004024375D1 (en) carboxamide
EG24928A (en) Heterocyclic inhibitors of mek and methods of use thereof
NO20076418L (en) Heterocyclic compounds as agonists for the thyroid receptor
GEP20074033B (en) Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
DE602004012858D1 (en) 2-AMINOBENZOTHIAZOLE AS CB1 RECEPTOR INVERSE AGONISTS
HRP20041026A2 (en) Polycyclic compounds as potent alpha2-adrenoceptor antagonists
SE0203302D0 (en) Novel Compounds
SE0104333D0 (en) Therapeutic agents
SE0301371D0 (en) New Compounds
JP2004517081A5 (en)
SE0402972D0 (en) Novel compounds